Clinical actionability enhanced through deep targeted sequencing of solid tumors.
暂无分享,去创建一个
Yuan Qi | Ken Chen | Zechen Chong | Funda Meric-Bernstam | Gordon B Mills | Hao Zhao | Amber Johnson | Amber M. Johnson | Rajyalakshmi Luthra | Michael A Davies | Tenghui Chen | Agda Karina Eterovic | John Mendelsohn | Wanding Zhou | G. Mills | K. Aldape | Y. Qi | Zechen Chong | Wanding Zhou | J. D. de Groot | F. Meric-Bernstam | Hao Zhao | Ken Chen | S. Kopetz | J. Mendelsohn | K. Shaw | M. Routbort | A. Eterovic | Qingxiu Zhang | S. Moulder | Tenghui Chen | Xiaofeng Zheng | R. Luthra | Yong Mao | Scott Kopetz | John de Groot | Kenneth D Aldape | Mark J Routbort | Xiaofeng Zheng | Yong Mao | Stacy Moulder | Qingxiu Zhang | Nader Ezzeddine | Lin-Ya Tang | Ravi Vinod | Carol J Farhangfar | Kenna Mills Shaw | Nader Ezzeddine | Lin-ya Tang | M. Davies | C. Farhangfar | R. Vinod | A. K. Eterovic
[1] Steven J. M. Jones,et al. Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.
[2] Ralf Herwig,et al. Targeted high throughput sequencing in clinical cancer Settings: formaldehyde fixed-paraffin embedded (FFPE) tumor tissues, input amount and tumor heterogeneity , 2011, BMC Medical Genomics.
[3] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[4] Ken Chen,et al. Clonal architecture of secondary acute myeloid leukemia. , 2012, The New England journal of medicine.
[5] Rashmi Kanagal-Shamanna,et al. Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. , 2013, The Journal of molecular diagnostics : JMD.
[6] Joshua F. McMichael,et al. Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing , 2011, Nature.
[7] Elaine R. Mardis,et al. A decade’s perspective on DNA sequencing technology , 2011, Nature.
[8] Nikhil Wagle,et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. , 2012, Cancer discovery.
[9] K. Kinzler,et al. Cancer Genome Landscapes , 2013, Science.
[10] Peter Donnelly,et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas , 2013, Nature Genetics.
[11] S. Gabriel,et al. Pan-cancer patterns of somatic copy-number alteration , 2013, Nature Genetics.
[12] Ken Chen,et al. Implementation of biomarker-driven cancer therapy: existing tools and remaining gaps. , 2014, Discovery medicine.
[13] Alex M. Fichtenholtz,et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing , 2013, Nature Biotechnology.
[14] M. Stratton,et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website , 2004, British Journal of Cancer.
[15] Jeffrey J Meyer,et al. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012. (5) , 2013 .
[16] G. Mills,et al. CanDrA: Cancer-Specific Driver Missense Mutation Annotation with Optimized Features , 2013, PloS one.
[17] T. Hubbard,et al. A census of human cancer genes , 2004, Nature Reviews Cancer.
[18] Benjamin J. Raphael,et al. Mutational landscape and significance across 12 major cancer types , 2013, Nature.
[19] Irmtraud M. Meyer,et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers , 2012, Nature.
[20] Douglas A Lauffenburger,et al. Addressing genetic tumor heterogeneity through computationally predictive combination therapy. , 2013, Cancer discovery.
[21] Lee T. Sam,et al. Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study , 2011, Science Translational Medicine.
[22] The Bioethics Commission on Incidental Findings , 2013, Science.
[23] S. Gabriel,et al. Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.